A study conducted at the GW Cancer Institute identified issues faced by cancer care institutes in adopting patient-centered care programs.
In order to meet new cancer program accreditation standards, institutions have placed new focus on patient navigation, psychosocial distress screening, and survivorship care plans. Recently published research by the George Washington University (GW) Cancer Institute found these new programs are experiencing “growing pains.” The results of a nationwide survey conducted by the GW Cancer Institute and reviewed in the Journal of Oncology Navigation and Survivorship, found that health care professionals could most benefit from greater evaluation of their program’s impact.
"This national study from GW Cancer Institute's Center for the Advancement of Cancer Survivorship, Navigation and Policy provides insights into current approaches and barriers for patient-centered care in practice," said Mandi Pratt-Chapman, M.A., director of the GW Cancer Institute. "These findings will help us focus our collective efforts to address identified gaps such as navigation role delineation and how to measure value of these programs."
Press release:
Source: George Washington University
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
2 Commerce Drive
Cranbury, NJ 08512